Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sarah Goldberg MD, MPH

Sarah B. Goldberg MD, MPH

Associate Professor of Medicine (Medical Oncology), Yale School of Medicine/Yale Cancer Center, New Haven, Connecticut

Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. She specializes in the treatment of thoracic malignancies, including lung cancer, mesothelioma, and thymoma. Her research interests include personalized medicine and immunotherapy for non–small cell lung cancer and identification of biomarkers that predict response to treatment.

Disclosures

  • Research Funding: AstraZeneca; Boehringer Ingelheim; Mirati
  • Advisory Board and Consultancy: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Amgen; Blueprint Medicines; Sanofi Genzyme; Daiichi-Sankyo; Takeda; Janssen; Summit Therapeutics; Merck; Regeneron

Recent Contributions to PracticeUpdate:

  1. Monitoring Immunotherapy Outcomes With Circulating Tumor DNA
  2. Immunotherapy Versus Chemotherapy Plus Immunotherapy for Advanced Lung Cancer
  3. 5-Year Overall Survival for Patients With Advanced NSCLC Treated With Pembrolizumab
  4. Trial Updates on Pembrolizumab for Brain Cancer Metastases
  5. Erlotinib Plus Ramucirumab for EGFR Mutant Lung Cancer
  6. Neoadjuvant Atezolizumab for Patients With Non-Small Cell Lung Cancer
  7. Pembrolizumab vs Chemotherapy for Previously Untreated PD-L1–Expressing, Locally Advanced or Metastatic NSCLC

Most Read This Week

Recently Updated